| DC Field | Value | Language |
|---|
| dc.contributor.author | Romaschenko, O. V. | - |
| dc.contributor.author | Pokrovsky, M. V. | - |
| dc.contributor.author | Nadezhdin, S. V. | - |
| dc.contributor.author | Rumbesht, V. V. | - |
| dc.contributor.author | Zhernakova, N. I. | - |
| dc.contributor.author | Alferov, P. K. | - |
| dc.contributor.author | Grischenko, N. D. | - |
| dc.date.accessioned | 2023-03-17T12:57:56Z | - |
| dc.date.available | 2023-03-17T12:57:56Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.citation | Personalized approaches to the use of the antioxidant ethoxidol in patients with coronary heart disease / O.V. Romaschenko [et al.] // Journal of Nanostructures. - 2022. - Vol.12, №2.-P. 343-352. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/52225 | - |
| dc.description.abstract | The personalized approach to the choice of drugs in the treatment of patients with coronary heart disease (CHD) is designated as "diamond". How this relates to the antioxidant drug ethoxidol is to be sanctified in this article. To develop a personalized approach to the use of ethoxidol in patients with CHD based on the definition of criteria for predicting the cytoprotective properties of this drug when tested in vitro | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | antioxidants | ru |
| dc.subject | coronary heart disease | ru |
| dc.subject | in vitro research | ru |
| dc.subject | leukocytes | ru |
| dc.subject | microscopy | ru |
| dc.subject | personalized pharmacotherapy | ru |
| dc.title | Personalized approaches to the use of the antioxidant ethoxidol in patients with coronary heart disease | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
